Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study-MedSci.cn

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study

Lu, J; Fu, WJ; Li, W; Hu, JD; An, G; Wang, YF; Fu, CC; Chen, LJ; Jin, J; Cen, XN; Ge, Z; Cai, Z; Niu, T; Qi, M; Sun, S; Gai, X; Liu, WP; Liu, WY; Yang, X; Huang, XJ

Huang, XJ (corresponding author), Peking Univ, Collaborat Innovat Ctr Hematol, Natl Clin Res Ctr Hematol Dis, Peoples Hosp, Xizhimen South St, Beijing 100000, Peoples R China.

Abstract

Daratumumab plus bortezomib/dexamethasone (D-Vd) significantly improved outcomes versus Vd in patients with relapsed or refractory multiple myeloma (R......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study

科室

工具

服务